New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
06:31 EDTAGN, VRX, NSRGY, JNJValeant prepared to make higher offer for Allergan, says Wells Fargo
Wells Fargo said it left Valeant (VRX) and Pershing Square's sell-side meeting Friday with the impression that Valeant is prepared to go higher than the current offer for Allergan (AGN), which it notes is about $159 per share at closing prices on April 25. Wells pointed out that Valeant and Pershing indicated that Nestle (NSRGY) was the most likely potential additional bidder for Allergan followed by Johnson & Johnson (JNJ). Wells has an Outperform rating on Allergan.
News For AGN;VRX;NSRGY;JNJ From The Last 14 Days
Check below for free stories on AGN;VRX;NSRGY;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 18, 2014
12:51 EDTAGN, VRXKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTVRX, AGNSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
06:41 EDTNSRGYNestle U.S. chocolate goals curbed by Lindt acquisition, Bloomberg says
Nestle, who usually aims to be first or second in all of its divisions, isnít even close in the U.S. chocolate candy industry, where the Swiss firm is shut-out by Mars and Hershey (HSY), reported Bloomberg. When Lindt & Spruengli finalizes its acquisition of Russell Stover Candies, Nestle will fall even deeper behind, by ranking fourth in the U.S. Reference Link
July 17, 2014
16:45 EDTAGN, VRXPershing Square looks to obtain consents for special meeting
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson weakness creates buying opportunity, says Argus
Subscribe for More Information
10:56 EDTJNJJohnson & Johnson reports 18% passive stake in Minerva
Subscribe for More Information
10:20 EDTAGNPershing sees coming 13-Fs to show long-term Allergan holders have been selling
Subscribe for More Information
09:00 EDTAGNAckman says large takeover by Allergan could be 'enormously value destructive'
08:44 EDTAGNPershing says special meeting warranted given 'poor governance' at Allergan
Subscribe for More Information
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:00 EDTAGN, VRXPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTVRX, AGNAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTVRX, AGNPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTAGN, VRXTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:31 EDTAGNPershing Square Capital Management holds analyst/industry conference call
Subscribe for More Information
09:16 EDTAGN, VRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allerganís corporate governance.
08:55 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Leerink views the post-earnings pullback in shares of Johnson & Johnson as a buying opportunity. The firm expects "several" more quarters of outperformance and raised its price target for the stock to $115 from $110. It keeps an Outperform rating on J&J.
08:16 EDTVRX, AGNLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTVRX, AGNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:25 EDTJNJJohnson & Johnson should be bought on pullbacks, says RBC Capital
RBC Capital believes that Johnson & Johnson reported strong Q2 results, and the company raised its estimates for the company. The firm continues to recommend buying the stock on pullbacks.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use